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Genetically manipulated phages 
with improved pH resistance for 
oral administration in veterinary 
medicine
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Servé W. M. Kengen2, Joana Azeredo1 & Leon D. Kluskens1
Orally administered phages to control zoonotic pathogens face important challenges, mainly related 
to the hostile conditions found in the gastrointestinal tract (GIT). These include temperature, salinity 
and primarily pH, which is exceptionally low in certain compartments. Phage survival under these 
conditions can be jeopardized and undermine treatment. Strategies like encapsulation have been 
attempted with relative success, but are typically complex and require several optimization steps. Here 
we report a simple and efficient alternative, consisting in the genetic engineering of phages to display 
lipids on their surfaces. Escherichia coli phage T7 was used as a model and the E. coli PhoE signal peptide 
was genetically fused to its major capsid protein (10 A), enabling phospholipid attachment to the phage 
capsid. The presence of phospholipids on the mutant phages was confirmed by High Performance Thin 
Layer Chromatography, Dynamic Light Scattering and phospholipase assays. The stability of phages 
was analysed in simulated GIT conditions, demonstrating improved stability of the mutant phages 
with survival rates 102–107 pfu.mL−1 higher than wild-type phages. Our work demonstrates that phage 
engineering can be a good strategy to improve phage tolerance to GIT conditions, having promising 
application for oral administration in veterinary medicine.
Bacteriophages or phages are considered one of the most promising alternatives to antibiotics due to their natural 
antimicrobial properties. These bacteria-infecting viruses of high-specificity have applications on a wide range of 
fields including agriculture, food, and human or animal therapy1.
In the veterinary field, phage therapy has been evaluated against several zoonotic pathogens, with the intent 
to control transmission of diseases to humans and to reduce economic loss2–5. Some successful applications 
have been reported, including treatment of infections of Escherichia coli in calves, pigs, lambs and poultry6–9, 
of Campylobacter in poultry10,11, of Salmonella in poultry and pigs12,13, Clostridium perfringens in poultry14 and 
Pseudomonas aeruginosa in dogs15. Currently, some phage products are already being commercialized (such 
as BioTector®S1 and INT-401TM to control Salmonella in poultry feed and Clostridium perfringens infections, 
respectively)14.
Despite some successful attempts, phage therapy in veterinary has presented variable results. These disparities 
are in part due to the severe physiochemical conditions that phages encounter en route through the digestive sys-
tem and at the site of infection16,17. Indeed, phage viability and survival have been shown to be affected by factors 
as acidity and temperature, which cause modifications on phage’s structural components and nucleic acids18. 
Acidity of the gastric environment of most animals is a major concern for oral administration of phages, since the 
low pH values significantly reduce phage titre and proliferation19–22. The body temperature of animals (e.g. 38 °C 
in dogs and 42 °C in chickens) is also a parameter that can affect treatment efficacy since temperatures above the 
optimum prolong the phage’s latent period, and below the optimum reduce phage penetration and consequent 
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proliferation. Enzymes found in the gastrointestinal tract (GIT), such as pepsin in gastric fluid, and amylase, 
lipase and protease in pancreatic fluid, may also cause degradation of phages23–26.
Because of the challenges faced by orally-delivered phages, it is desirable to provide additional protection to 
enhance their survival in the GIT. Phage encapsulation in natural biopolymer-derived matrices have been used as 
a strategy to improve phage stability27–31. An increased survival of phages has been obtained with this technology 
in the GIT of cattle, pigs and poultry27,32,33. However, for this type of strategy, the selection of the biopolymer is 
critical, and some important features have to be met, such as the ability to be synthesized under mild environ-
mental conditions, and to be easily tailored, non-toxic and environmental friendly (e.g. not requiring the use of 
organic solvents34)29,35.
Here we suggest an alternative to encapsulation, based on the display of phospholipids on the surface of the 
phages by genetic engineering. Such a “natural coating” may provide the phage with added protection against 
the acidic environment and other hostile conditions found in the GIT of animals, potentially without affecting 
the phage’s infection ability. The genetic engineering of lytic phages has proven difficult in the past, but with the 
development of new techniques such as Bacteriophage Recombineering of Electroporated DNA (BRED)36,37 it is 
now becoming a simple process, cheaper than encapsulation and without special requirements for equipment or 
reagents.
In this work we used the well-known E. coli phage T7 as a model, and modified its genome with the E. coli 
outer membrane phosphoporin protein E (PhoE) signal peptide (sequence MKKSTLALVVMGIVASASVQA). 
Signal peptides are temporary N-terminal extensions of proteins that are destined to be exported from the cyto-
plasm of bacteria38,39. These peptides have little sequence homology but they share certain properties such as a 
positively charged N-terminal region, a central hydrophobic core, and a more polar C-terminal region containing 
the cleavage site40,41. Signal peptides in E. coli, as the PhoE signal peptide, are thought to be directly involved in 
the binding of proteins to the membrane by electrostatic interactions between the N-terminus and anionic mem-
brane phospholipids, thereby initiating membrane translocation of the protein42. Biophysical studies have also 
demonstrated a strong interaction between isolated signal peptides and lipids of model membrane systems43–45. 
Here we intend to explore the properties of the PhoE signal peptide by fusing it to the major capsid protein (10 A) 
of phage T7. We hypothesize that the presence of the PhoE signal peptide on the capsid of the phage may provide 
added protection to the phage by the interaction of the signal with E. coli phospholipids. These lipids, which are 
synthesized at the cytoplasmic side of the inner membrane46, may be acquired during phage replication inside the 
bacteria, thereby creating a lipidic coating (Supplementary Fig. S1). Indeed, the attachment of phospholipids to 
the major capsid protein was confirmed by surface analysis using High Performance Thin Layer Chromatography 
(HPTLC), Dynamic Light Scattering (DLS) and phospholipase assays. Moreover, these mutant phages demon-
strated a higher stability than the wild-type phages under different conditions simulating those found in animal’s 
GIT (pH, temperature and enzymes). Altogether, we show that lipid coating of phages obtained by genetic manip-
ulation represents a promising alternative to encapsulation for orally delivered phage therapy.
Results and Discussion
Oftentimes, acid-lability contributes to a poor efficacy of phage therapy on the GIT of animals. In this study we 
therefore focused on the development of a solution to overcome acid lability of orally administered phages. For 
that we fused the E. coli PhoE signal peptide to the major capsid protein (gp10A), using E. coli phage T7 as a 
model phage. Using BRED we inserted the PhoE signal peptide into the T7 genome, fused to the major capsid 
protein (gp10A), obtaining the mutant phage T7::PhoE. When transcribed, the assembled mutant phage may 
bind phospholipids from the inner leaflet of the cytoplasmic membrane upon ionic interaction with the polar 
head group of e.g. phosphatidylglycerol (main anionic phospholipid in E. coli and hence expected to be the phos-
pholipid attached to the mutant phages).
Assessment of phage mutation, stability and infectivity. After BRED the insertion of the PhoE sig-
nal peptide into the T7 phage genome was confirmed by PCR (Supplementary Fig. S2), and by sequencing we 
could show that the mutation remained stable for at least 10 generations.
Since the generated mutations may have affected the infection ability of the phages, the infectivity of the 
mutant phage T7::PhoE was evaluated and compared to the wild-type T7. The infection parameters were assessed 
through a one-step growth curve. For both phages the latent period was established at approximately 15 min, 
with an eclipse time around 10 min, and a burst size of 253 ± 30 for T7 and 243 ± 92 for T7::PhoE. Apparently, 
the mutant phages showed an infectivity identical to the wild type phage, indicating no effect of the mutation on 
phage replication. Further results obtained are therefore not a consequence of any alteration on the capacity of 
the phage to infect.
Confirmation of phospholipids on the mutant phage capsid. The wild-type T7 and mutant 
T7::PhoE phages were inspected by transmission electron microscopy (TEM) in an attempt to visualize the 
presence of a coating surface around the mutant phages. However, no clear differences could be seen by TEM 
(see Supplementary Fig. S3). Osmium tetroxide staining was also attempted due to its capacity to stain lipids; 
however, again, no differences could be seen (Supplementary Fig. S3). So other strategies were followed to check 
for the presence of lipids on the mutant phages, namely surface analysis by HPTLC, DLS and a phospholipase 
assay.
For HPTLC, the total lipids were extracted from wild-type T7 and T7::PhoE phages, as well as from the host 
bacteria, and analysed on HPTLC plates. The separated lipids were visualized by sulfuric acid charring. The 
chromatogram (Fig. 1) shows an increased lipid content of the mutant phages (Fig. 1, lane 3) compared to the 
wild-type control (Fig. 1, lane 2).
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Here we observed an increased intensity of one or several lipids/phospholipids species in the mutant, which 
is comparable to the E. coli total lipid profile (Fig. 1, lane 1). Of interest is the fact that one specific lipid species 
increased its intensity in particular (arrow head in Fig. 1), as the signal peptide is known to bind only anionic 
lipids. This data supports the incorporation of E. coli lipids/phospholipids onto the capsid structure of the mutant 
phage.
Additionally, the zeta potential of the wild-type and mutant phages was determined by DLS (Fig. 2). The 
charge of the phage particles was significantly different (P = 0.0154), with average values of − 5.49 mV and 
− 8.69 mV, for T7 and T7::PhoE respectively. Since the PhoE signal peptide has a predicted positive net charge 
of + 2 mV (http://pepcalc.com/protein-calculator.php), these results indicate that another factor is reducing 
the mutant phage’s overall surface charge, which may well be a consequence of attached lipids/phospholipids, 
recruited by the PhoE signal peptide. For instance, the most prevalent anionic phospholipid in E. coli, phosphati-
dylglycerol, present at the cytoplasmic side of the inner membrane, has been reported to have a negative charge 
Figure 1. HPTLC chromatogram of total lipid extracts from phage isolates. Lane 1: Escherichia coli BL21 
positive control, lane 2: wild-type phage T7; lane 3: mutant phage T7::PhoE. Arrow head indicates the lipid 
species that is particularly enriched in the T7::PhoE mutant.
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Figure 2. Zeta potential of phages T7 (wild-type) and T7::PhoE (mutant) determined by DLS. Statistical 
differences (P < 0.05) obtained using t-test analysis are represented by *.
www.nature.com/scientificreports/
4Scientific RepoRts | 6:39235 | DOI: 10.1038/srep39235
at the phosphate moiety of the head groups, which may be responsible for the increased negative charge found by 
DLS for the mutant phages.
Phage survival at different pH values. Phages can become irreversibly damaged by exposure to low pH 
values (as well as other conditions, see review17), a condition typically found in the GIT of animals. The display of 
a coating on the surface of phages may provide stability, protecting them from these conditions. To evaluate this, 
the wild-type and mutant phages were used in in vitro survival assays simulating different conditions encountered 
along the GIT of animals. The conditions tested included: i) temperature, ranging from 38 °C to 42 °C to represent 
typical body temperatures of different animals; ii) pH, ranging from 2.5 to 5.7 to simulate the acidic environment 
found in different compartments of the GIT; and iii) time, ranging from 15 to 1440 min (24 h) to represent dif-
ferent residence times of each compartment of the GIT. Results can be seen in Figs 3, 4, 5 and 6. Under the most 
severe condition, at a pH value of 2.5 (Fig. 3), found for example in the gizzard of poultry, the wild-type phage’s 
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Figure 3. Survival of wild-type T7 and mutant T7::PhoE phages to different conditions that simulate 
those found in the GIT of animals: pH of 2.5, temperature range from 38 °C to 42 °C. Statistical differences 
(P < 0.05) obtained using t-test analysis are represented by *.
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Figure 4. Survival of wild-type T7 and mutant T7::PhoE phages to different conditions that simulate 
those found in the GIT of animals: pH of 3.5, temperature range from 38 °C to 42 °C. Statistical differences 
(P < 0.05) obtained using t-test analysis are represented by *.
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titre is completely lost in just 15 min, while the mutant phages can survive up to 30 min with a 106-fold decrease in 
titre. For pH values 3.5 (Fig. 4), 4.5 (Fig. 5) and 5.7 (Fig. 6), the mutant phage’s titre is generally reduced by a factor 
of 101 or 102, whereas the wild-type phage’s titre generally reduces by a factor of 102 to 104. This average 100-fold 
difference between mutants and wild-type phages can have a significant impact on the course of oral phage ther-
apy. In fact, it is reported that, for oral application of phages, doses as high as 1011–1013 pfus.mL−1 are required to 
ensure that a significant number of phages (at least 106) reaches the intestines46. So, the difference observed here 
for phage survival may potentially result in a higher amount of phages reaching the target site and consequently 
improves treatment efficacy (Fig. 3, 4, 5 and 6).
It is possible that the presence of the lipid/phospholipid coating the surface of the mutant phages limits the 
direct contact of the phage with the acidic environment, therefore resulting in the improved viability. Our results 
are comparable to those obtained by Dini et al.27 for phage CA933P, Ma et al.32 for phage Felix O1, and Samtlebe 
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Figure 5. Survival of wild-type T7 and mutant T7::PhoE phages to different conditions that simulate 
those found in the GIT of animals: pH of 4.5, temperature range from 38 °C to 42 °C. Statistical differences 
(P < 0.05) obtained using t-test analysis are represented by *.
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Figure 6. Survival of wild-type T7 and mutant T7::PhoE phages to different conditions that simulate 
those found in the GIT of animals: pH of 5.7, temperature range from 38 °C to 42 °C. Statistical differences 
(P < 0.05) obtained using t-test analysis are represented by *.
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et al. 31 for phage P008, using encapsulation methods. Both observed increased survival of encapsulated phages at 
acidic pH values when compared to free phages.
Also interesting to note are the strong differences between the mutant and wild-type phages observed for the 
higher temperatures and longer incubation times. This is particularly accentuated for pH 3.5 (Fig. 4), at tem-
peratures of 42 °C, where a 104 to 107 fold difference can be observed after 180 min and 1440 min of incubation, 
respectively. So it is possible that additionally to pH, the lipid coating provides protection against increased tem-
peratures, which may affect the activity of temperature-sensitive phages. This may be an important characteristic 
to be considered in therapeutic applications, especially due to the range of body temperatures observed in differ-
ent animals, making the mutant phages more broadly applicable, and tolerant to the high temperatures (fever) of 
the body when fighting an infection.
An important aspect to consider is that the lipid/phospholipid coating generated by our mutation only pro-
vides protection to the capsid of the phage. The tail and the fibres, which are the phage components responsible 
for recognition and infection in tailed phages47, are non-modified and therefore remain exposed to the acidic pH 
values. This suggests that damage caused by low pH values on phages is not necessarily a consequence of an effect 
on the phage’s proteinaceous structure, otherwise the tails would have been degraded and the phage would not 
infect. The damage may instead be elicited on the genetic material of the phage, with the phospholipid coating 
on the capsid preventing this effect. On the other hand, it is known that phages aggregate at acidic pH due to a 
protonation effect, adversely impacting their activity; with an increased negative charge in the mutant phages, it 
is possible that protonation is not sufficient to cause complete aggregation of the phages, thereby having a lower 
impact on their activity. To prove that phages retain their capacity to infect after being subjected to low pH values, 
we tested whether the mutant phages retained their capacity to multiply in the bacteria after being subjected to the 
acidic environment. After 3 h of incubation with the bacterial host, the phages’ titre increased 100-fold (data not 
shown). This indicates that the phages are still able to infect and multiply after being subjected to the acidic con-
ditions that may be encountered in the stomach, a promising result for the treatment of bacterial infections in the 
gut. So, the detrimental effect of an acidic pH must involve other factors, and should be explored in future studies.
Mutant phage sensitivity to phospholipases. The pH-resistant phenotype of the mutant phage demon-
strated above led us to further evaluate the hypothesis of it being caused by the presence of phospholipids attached 
to the PhoE signal on the capsid of the mutant. For this, reverting assays using enzymes able to specifically 
degrade phospholipids, i.e. phospholipases, were performed. In these assays, both wild-type and mutant phages 
were subjected to the activity of phospholipase A2. This enzyme recognizes and hydrolyses the sn-2 acyl bond of 
phospholipids, forming a fatty acid and a lysophospholipid. Figure 7 demonstrates that after phospholipase activ-
ity, the mutant phage presents a log survival similar to the wild-type phage (both subjected and non-subjected to 
the activity of phospholipase), and lower than the control mutant phage (not subjected to phospholipase). The 
reversion of the mutant phage to a pH-sensitive phenotype caused by the phospholipase further confirms the 
presence of phospholipids on the capsid of the mutant, and indicates their involvement on tolerance to low pH.
It must be pointed out that phospholipase A2 is present in the pancreatic fluids secreted into the gut48, and 
may thus revert the protected effect of phospholipids on phage capsids of the mutant phages. However, once in 
the gut, phages will no longer be subjected to low pH values and therefore do not require the additional protection 
provided by phospholipids. Thus it is expected than even if phospholipase A2 acts on T7::PhoE, the therapeutic 
effect of the phage will not be compromised.
Phage stability in enzymatic fluids and bile salts. Phages administered orally must withstand the pas-
sage through the gastric fluid to be of therapeutic use. This does not only mean survival at low pH values but also 
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resistance to hydrolytic enzymes as pepsin (stomach), lipase, amylase and protease (pancreas). Therefore, the 
stability of the wild-type and mutant phages under simulated gastric and pancreatic conditions was evaluated 
(Fig. 8a and b). Exposure to pancreatic enzymes (Fig. 8a) at concentrations within the range found in duode-
nal juice (around 1.4 ± 0.7 mg/mL49) had no major effect on the viability of either wild-type or mutant phages, 
although significant differences (P < 0.05) can be found between phages after 120 min of incubation. But in gen-
eral pancreatic enzymes do not appear to be a major concern for the oral delivery of phage T7, with less than 5% 
reduction in the phage titre.
On the other hand, gastric enzymes (Fig. 8b) lead to a substantial reduction in the number of wild-type T7 
at 90 min and 120 min, while the mutant T7::PhoE remained mostly unaffected (P < 0.05). As already discussed 
for pH survival, the presence of lipids/phospholipids on the surface of the mutant phages may limit the access of 
the enzymes to the phage and thereby prevent degradation. The protection provided by the lipid coating on the 
mutant phages appears to be similar27 or even superior32 to that observed with microencapsulation approaches, 
where the microencapsulated phages had a comparably higher rate of survival than free phages in simulated gas-
tric fluid, but still with partial loss of viability (2.58 log units after 1 h).
Bile acid is secreted into the GIT, where it works as an anionic surfactant. Some phages have already demon-
strated resistance to the effect of bile50 but others appear to be somewhat affected32. So in this assay the stabil-
ity of the wild-type T7 and mutant T7::PhoE in simulated bile fluid was determined (Fig. 8c). Bile salts affect 
the wild-type phage significantly more (P < 0.05) than the mutant phage after an incubation of 1 h, but shows 
similar effects after 3 h, with a viability reduction of about 16% (corresponding to 1 log). However, it should be 
emphasized that we used a bile concentration (2%) which exceeds to that found in bile produced in the organism 
(around 0.7%51), so the effect of bile salts on these phages is expected to be lower than those observed here.
In summary, in this study we demonstrate that an engineered phospholipid coating of the T7 phage acts as a 
protective barrier, significantly improving phage survival under conditions simulating those found on the GIT of 
different animals, in particular acidity and hydrolytic enzyme activity. Compared to other methods to date, such 
as microencapsulation, our approach has the advantages of process simplicity, with significantly less optimiza-
tion steps and a simple process for scale-up (requiring only phage amplification), being equally efficient but with 
improved viability/stability.
Importantly, we show that phage engineering may be a feasible, simple and cost-effective approach to improve 
phage properties for oral administration in animals. Furthermore, the insertion of the PhoE signal on the capsid 
of phage T7 allows future exploitation of the frameshifting on gene 10, characterized by the expression of two 
products, the major 10 A protein, and the minor 1α protein, which results in different phage phenotypes52. So, 
replication of the mutant T7::PhoE in other hosts (different E.coli strains) could change the copy number of 10 A 
resulting in different phenotypes of the same mutant. We hypothesize that such mechanism could be explored to 
relax or tighten the coating effect for other therapeutic applications and/or other administration routes. Other 
phages with this dynamic frameshifting, e.g T7-like phages. T3-like and T4-like phages can also be explored to 
display similar coatings for other applications.
Another relevant aspect not studied here is the possibility to increase phage-host encounters by sub-diffusive 
motion in mucosal surfaces53. The mucus rich environment in the GIT has been proven to be the principal 
location of most translocation events of bacterial pathogens. Future in vivo studies can test the ability of our 
mutant phage to survive for a longer period in the gut, by fast absorption to and diffusion into the mucosa, which 
increases the encounters with the pathogenic host and may improve the efficacy of phage therapy.
Methods
Buffers and media. Saline-Magnesium (SM) buffer, containing 100 mM NaCl, 8 mM MgSO4.7H2O and 
50 mM Tris (pH 7.5) was used for phage dilutions. Lysogeny broth (LB) medium54 was used for bacterial growth. 
Super Optimal broth with Catabolite repression (SOC) was used to recover cells after recombineering. Agar was 
used at a concentration of 1.2% in plates and 0.7% in soft agar. Ampicillin (Amp) was used at a final concentration 
of 100 μ g.mL−1. L-arabinose at 10% (w/v in water) was used to induce recombineering functions.
Bacteriophages, bacteria and plasmids. Phage T7 was kindly provided by Prof. Ian J. Molineux, 
University of Texas. The phage host was E. coli BL21 (Stratagene). Plasmid pKD46, an ampicillin-resistant and 
temperature sensitive plasmid that encodes the lambda Red genes (exo, beta and gam) was used to prepare recom-
bineering competent cells.
Preparation of recombineering competent E. coli BL21 cells. Electrocompetent E. coli BL21 cells 
were prepared as described previously, with minor modifications55. Briefly, cells were grown in LB medium to 
mid-log phase and harvested by centrifugation (3000 × g, 4 °C, 15 min). The culture was concentrated 500-fold 
by washing three times with ice-cold sterile 10% (v/v) glycerol, and suspended in a final volume of 80–300 μ L. 
Then, 100–500 ng of pKD46 were electroporated into aliquots of 20 μ L electrocompetent cells at 1.8 kV and 25 pF 
using a Gene Pulser XCell Microbial System (BioRad). Cells were recovered with SOC and incubated for 1–2 h 
at 37 °C, 200 rpm. Cells were spread in LB plates containing ampicillin (LB-Amp) and incubated overnight at 
30 °C. Transformed E. coli BL21::pKD46 colonies were picked and grown in fresh LB-Amp medium for a few 
hours, followed by plasmid extraction (NucleoSpin® Plasmid (NoLid) kit, Macherey-Nagel) and digestion with 
the restriction enzyme BamHI-HF (New England Biolabs) to confirm the presence of pKD46.
Construction of the recombineering substrates. For the construction of the recombineering sub-
strates, the primers (Life Technologies, Portugal) presented in Supplementary Table S1 were used at a concentra-
tion of 25 μ M for Knight - annealing and primer extension with Taq polymerase. The forward and reverse primers 
of the PhoE signal peptide were mixed with water, 10x buffer Taq A, dNTPs and Kapa Taq DNA polymerase 
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(Kapa Biosystems), and annealed and extended using the following program: 95 °C for 5 min; 5 cycles of 95 °C for 
30 s, 50 °C for 30 s, and 72 °C for 30 s; and 72 °C for 5 min. The resultant constructs were purified using the GRS 
PCR & Gel Band Purification Kit (Grisp) and sizes confirmed on a 1% SGTB agarose (Grisp) gel using the Low 
Molecular Weight DNA ladder (New England Biolabs).
Bacteriophage Recombineering of Electroporated DNA. Engineering of the phage T7 genome was 
based on the method described by Marinelli et al.36,37 with some modifications. Briefly, E. coli BL21::pKD46 was 
grown to early-log phase at 30 °C in 100 mL LB-Amp medium, and the expression of lambda Red by pKD46 was 
induced for 30 min with L-arabinose (0.1% final concentration). Cells were then infected with T7 at a multiplicity 
of infection (MOI) of 1–3 for the eclipse time (10 min). Cells were then made electrocompetent as described 
above. 100–500 ng of the substrate were electroporated into the electrocompetent cells at 1.8 kV and 25 pF, and 
cells were recovered with SOC medium for 1–2 h at 37 °C, 200 rpm. The suspension was then mixed with approx-
imately 3 mL soft agar and 100 μ L of an E. coli BL21 culture, poured onto LB plates, and incubated overnight at 
37 °C.
Recovery and confirmation of mutant phages. The phage plaques obtained were assessed for the pres-
ence of mutants by PCR. For this several phage plaques were picked and replicated in E. coli BL21 for 2–3 hours. 
Then phages were recovered by addition of chloroform, followed by centrifugation at 12,000 × g for 15 min, and 
collection of the supernatant. Phage’s DNA was quickly extracted using Proteinase K at 37 °C for 40 min, fol-
lowed by inactivation at 100 °C for 15 min. PCR reactions were performed using the confirmation primers of 
Supplementary Table S1 using Kapa Taq DNA polymerase, in reaction volumes of 25 μ L, at an annealing tem-
perature of 50 °C. Sizes were confirmed in a 1% SGTB agarose gel using the Low Molecular Weight DNA ladder.
Phage purification by Cesium Chloride density gradient centrifugation. The mutant phages were 
purified by cesium chloride density gradient centrifugation. A step gradient of cesium chloride solutions (5.7 mL) 
was layered on Beckman centrifuge tubes, from the least to the most dense (ρ = 1.33, 1.45, 1.50 and 1.70 g.mL−1), 
adding each new layer to the bottom of the tube. The phage solution (15.2 mL containing 0.5 g of cesium chloride 
per mL of solution to avoid osmotic shock) was carefully layered over the gradient. The tubes were centrifuged 
at 28,000 × g for 3 h at 4 °C (Beckman Optima Ultracentrifuge XL-80K) in a SW28 rotor. After centrifuging, the 
band formed by the purified phage was recovered using a syringe with a 20 gauge needle to perforate the side of 
the centrifuge tubes. Cesium chloride was removed by dialysis against SM buffer at 4 °C.
Stability of the mutation. The stability of the mutation was assessed over several generations. For this, the 
T7::PhoE phage was propagated on its host for 4–6 h, followed by centrifugation (6000 × g, 10 min, 4 °C) and fil-
tration (0.2 μ m) for phage recovery. This procedure was repeated several times, using the phage obtained from the 
previous propagation. The presence of the mutation was confirmed by PCR, as described above, and confirmed 
by sequencing at StabVida (Portugal). Each propagation of 4–6 hours was considered as one phage generation, 
and a total of 10 generations were assessed.
Transmission electron microscopy. The mutant and wild type-phages were observed by TEM. For this, 
15 μ L of each purified phage sample were transferred to a 400 mesh copper grid with a pure carbon film (Electron 
Microscopy Sciences), incubated for three minutes on the grid and removed using filter paper. Grids were then 
washed with two drops of Milli-Q water and the water removed using filter paper. Then, four assessments were 
performed: i) no treatment, with samples on grid left to dry without further treatment; ii) negative staining with 
1% uranyl acetate solution, performed for 30 seconds followed by removal of all liquid using filter paper; iii) expo-
sure of the dried grids to osmium vapours (from recrystallized osmium tetroxide) for 1.5 h; and iv) incubation 
with glutaraldehyde/paraformaldehyde fixative for 10 min, washing with two drops of water, drying and exposure 
for 1.5 hours to osmium vapor. Imaging was performed using a JEOL JEM 1011 transmission electron microscope 
(JEOL Ltd.).
High Performance Thin Layer Chromatography. Normalized (same concentration) purified phage iso-
lates were freeze-dried overnight at − 52 °C. Total lipid extracts were prepared according to the lipid extraction 
protocol by Bligh and Dyer56. Briefly, the freeze-dried phages were dissolved in 1 mL Milli-Q water, re-suspended 
in 3.75 mL chloroform-methanol (1:1) and shaken vigorously. Then, 1.25 mL chloroform and 1.25 mL demin-
eralized water were added and the samples vigorous vortexed. Two phases were separated by centrifugation at 
1000 × g for 5 min. The chloroform phase was collected and washed once with 2.25 mL authentic upper phase. 
The chloroform phase was again isolated by centrifugation and evaporated under a stream of nitrogen. The lipid 
pellet was subsequently dissolved in 100 μ L methanol and centrifuged briefly to pellet insoluble particles. Five μ L 
total lipid extract were spotted on an activated silica60 HPTLC plate (Merck Millipore, VWR). Chromatograms 
were developed with a hexane/ethyl acetate (7:3) mobile phase. The dried HPTLC plate was sprayed with a mist 
of 20% sulfuric acid in ethanol and charred with a heat blower at 160 °C.
Dynamic light scattering to determine phage charge. DLS was performed to determine possible 
changes on the surface charge of the mutant phage caused by the incorporation of phospholipids on the capsid. 
For this, phage stocks were diluted in sterile Milli-Q water to obtain a phage concentration of 109 pfu.mL−1. These 
concentrated phage solutions were used for the measurement of zeta potential in disposable Folded Capillary 
Cells (Malvern Instruments, DTS1070) using a Zetasizer Nano ZS (Malvern Instruments). Measurements were 
made in triplicate, in three independent experiments, at a temperature of 25 °C.
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Mutant phage infectivity. To evaluate potential changes in the mutant’s phage infectivity, the one-step 
growth curve of the wild-type T7 and mutant T7::PhoE was determined as previously described with slight modi-
fications57. Briefly, an overnight culture of BL21 was diluted 1:20 in LB medium and grown at 37 °C, 200 rpm until 
an OD600 of 0.35. Bacteria were infected with the wild type or mutant phages at an MOI of 0.001. Samples were 
taken at short time intervals for a total of 90 min, immediately 10-fold serially diluted in SM buffer, and the phage 
titre determined using the double agar technique. The latent period, eclipse time and burst size of the phages was 
determined from the one step growth curve as described by Ellis and Delbrück (1939). The experiments were 
performed in triplicate and the results presented as mean ± standard deviation.
Phage survival at different pH values. Phage solutions of wild-type T7 and mutant T7::PhoE were pre-
pared at initial concentrations of 108 pfu.mL−1 in 0.2% (wt/vol in water) NaCl adjusted to different pH values 
(2.5, 3.5, 4.5, and 5.7) using hydrochloric acid, and incubated at different temperatures (38, 40, and 42 °C), with 
rocking, to simulate conditions encountered in the GIT of animals (see ref. 58 for more information on these 
conditions). Samples were taken at different time periods (15, 30, 45, 60, 75, 120, 180, 240, 300 and 1440 min) and 
immediately 10-fold serially diluted in SM buffer for phage titre determination. The experiments were performed 
in triplicate.
Phage capacity to amplify after being subjected to acidic conditions. Phage solutions of wild-type 
T7 and mutant T7::PhoE were prepared at initial concentrations of 108 pfu.mL−1 in 0.2% (wt/vol in water) NaCl 
adjusted to a pH of 4.5 and incubated at 40 °C with rocking for 3 hours. Then 200 μ L of each solution were added 
to 5 mL of an E. coli BL21 culture with an optical density at 600 nm of 0.3, and incubated for 3 h to assess the 
capacity of the phages to amplify after being subjected to acidic pH, by phage titre determination.
Reverting phenotype assays with phospholipase. The presence of phospholipids on the capsid of 
the mutant phages was assessed by enzymatic degradation with an enzyme (phospholipase) that specifically 
cleaves phospholipids. For this, wild-type and mutant phages, at initial concentrations of 108 pfu.mL−1, were sub-
jected to the activity of Phospholipase A2 (Sigma-Aldrich) at a concentration of 10 U/mL, in 0.2% (wt/vol) NaCl 
(pH of 7). Solutions were incubated for 1 h at 37 °C, added to LB adjusted to a pH of 4 and again incubated at 
37 °C. Samples were taken after 0, 60, 180 and 300 min, and immediately 10-fold serially diluted in SM buffer for 
phage titer determination using the double agar overlay plaque assay as described by Kropinski et al.59. Control 
solutions without phospholipase were used. The experiments were performed in triplicate and the results pre-
sented as mean log survival ± standard deviation.
Phage stability in enzymatic fluids. The stability of the wilt type and mutant phages in gastric and pan-
creatic enzymatic conditions was assessed. For this, simulated gastric fluid (SGF) comprised of 3.2 mg.mL−1 pep-
sin (Amresco) in 0.2% (wt/vol) NaCl at pH 3.5, and artificial pancreatic fluid (APF) comprised of 1 mg.mL−1 
pancreatin (Biocatalysts) in 0.2% (wt/vol) NaCl at pH 8.0 were prepared. Phages were added to the pre-warmed 
solutions at 37 °C at a concentration of 108 pfus.mL−1 and incubated at 37 °C. Samples were taken at 0, 5, 30, 60, 
90 and 120 min and immediately 10-fold serially diluted in SM buffer to determine phage titre. Controls with the 
same conditions but without the enzymes were used. The experiments were repeated twice and the results pre-
sented as mean log survival ± standard deviation of the phages in the enzymatic fluids compared to the respective 
controls.
Phage stability in bile salts. The stability of the wild type and mutant phages in bile salts was determined. 
For this, simulated bile fluid (SBF) comprised of 2% (wt/vol) porcine bile extract (Sigma-Aldrich) was prepared. 
Phages were added to the pre-warmed solution at 37 °C at a concentration of 108 pfus.mL−1 and incubated at 
37 °C. Samples were taken at 0, 1 and 3 h and immediately 10-fold serially diluted in SM buffer to determine phage 
titre. Controls with the same conditions but without the bile salts were used. The experiments were repeated twice 
and the results presented as mean log survival ± standard deviation of the phages in bile salts compared to the 
control.
Statistical analysis. Statistical analysis of the data was performed using the independent samples t-test of 
the software GraphPad Prism 5, considering a significance level of 95%.
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